Chart of Day: Amgen (AMGN) – 3/26

Oversold shares of Amgen (AMGN) could see a boost this week.

All on the news it wants to get in on the booming weight loss drug market. 


As noted by CNBC, “The biotech company is testing an injectable treatment that helps people lose weight differently from the existing injections from Novo Nordisk and Eli Lilly, and other obesity medicines in development. Amgen’s treatment, called MariTide, also appears to help patients keep weight off after they stop taking it.  The drug maker is also testing its drug to be taken once a month or even less frequently, which could offer more convenience than the weekly medicines on the market.”

With that, the oversold stock may be a solid long term bet on the growing obesity drug market.

In addition, as noted by, “Goldman Sachs upgraded Amgen to Conviction Buy from Buy with a $350 price target.”

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.